JP2000512648A - ピペリジン酢酸誘導体および血栓障害の治療におけるそれらの使用 - Google Patents

ピペリジン酢酸誘導体および血栓障害の治療におけるそれらの使用

Info

Publication number: JP2000512648A
Authority: JP; Japan
Prior art keywords: piperidin; formula; compound; indazol; acetic acid
Prior art date: 1996-06-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP10502284A

Other languages

English (en)

Japanese (ja)

Inventor

デイビッド、ジョージ、アラン

コリン、デイビッド、エルドレッド

ブライアン、デイビッド、ジュドキンス

ウイリアム、レオナルド、ミッチェル

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Glaxo Group Ltd

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-06-21

Filing date

1997-06-19

Publication date

2000-09-26

1996-06-21 Priority claimed from GBGB9613017.4A external-priority patent/GB9613017D0/en

1996-06-21 Priority claimed from GBGB9613095.0A external-priority patent/GB9613095D0/en

1996-06-21 Priority claimed from GBGB9613018.2A external-priority patent/GB9613018D0/en

1997-06-19 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2000-09-26 Publication of JP2000512648A publication Critical patent/JP2000512648A/ja

Status Pending legal-status Critical Current

Links

238000011282 treatment Methods 0.000 title claims abstract description 14
208000007536 Thrombosis Diseases 0.000 title claims abstract description 13
VRDBIJCCXDEZJN-UHFFFAOYSA-N 2-piperidin-1-ylacetic acid Chemical class OC(=O)CN1CCCCC1 VRDBIJCCXDEZJN-UHFFFAOYSA-N 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 168
150000003839 salts Chemical class 0.000 claims abstract description 42
238000000034 method Methods 0.000 claims abstract description 31
239000012453 solvate Substances 0.000 claims abstract description 26
239000003814 drug Substances 0.000 claims abstract description 17
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims abstract 2
-1 2-piperidin-4-yl-ethyl Chemical group 0.000 claims description 35
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 31
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 24
229920002554 vinyl polymer Polymers 0.000 claims description 17
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 12
239000001257 hydrogen Substances 0.000 claims description 10
229910052739 hydrogen Inorganic materials 0.000 claims description 10
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
125000006239 protecting group Chemical group 0.000 claims description 6
102000003886 Glycoproteins Human genes 0.000 claims description 5
108090000288 Glycoproteins Proteins 0.000 claims description 5
241001465754 Metazoa Species 0.000 claims description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
238000006243 chemical reaction Methods 0.000 claims description 4
102000006495 integrins Human genes 0.000 claims description 4
108010044426 integrins Proteins 0.000 claims description 4
HRBXFFUAVXSJLI-UHFFFAOYSA-N 2-[4-[3-methylsulfonyl-5-(2-piperidin-4-ylethyl)indazol-1-yl]piperidin-1-yl]acetic acid Chemical compound C12=CC=C(CCC3CCNCC3)C=C2C(S(=O)(=O)C)=NN1C1CCN(CC(O)=O)CC1 HRBXFFUAVXSJLI-UHFFFAOYSA-N 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
230000001404 mediated effect Effects 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
239000000969 carrier Substances 0.000 claims description 2
150000002431 hydrogen Chemical class 0.000 claims description 2
239000002243 precursor Substances 0.000 claims description 2
XMFZLJKDRKWLFH-UHFFFAOYSA-N 2-[4-[3-carbamoyl-5-(2-piperidin-4-ylethyl)indazol-1-yl]piperidin-1-yl]acetic acid Chemical compound C12=CC=C(CCC3CCNCC3)C=C2C(C(=O)N)=NN1C1CCN(CC(O)=O)CC1 XMFZLJKDRKWLFH-UHFFFAOYSA-N 0.000 claims 2
LKANVFBUWHBRSO-NSCUHMNNSA-N c1c2c(S(=O)(=O)C)nn(C3CCN(CC(O)=O)CC3)c2ccc1\C=C\C1CCNCC1 Chemical compound c1c2c(S(=O)(=O)C)nn(C3CCN(CC(O)=O)CC3)c2ccc1\C=C\C1CCNCC1 LKANVFBUWHBRSO-NSCUHMNNSA-N 0.000 claims 1
239000008177 pharmaceutical agent Substances 0.000 claims 1
230000008569 process Effects 0.000 abstract description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 73
239000000203 mixture Substances 0.000 description 54
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 52
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 47
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 37
239000000243 solution Substances 0.000 description 32
239000012265 solid product Substances 0.000 description 28
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 26
238000001819 mass spectrum Methods 0.000 description 26
235000019439 ethyl acetate Nutrition 0.000 description 25
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
239000000725 suspension Substances 0.000 description 23
239000000047 product Substances 0.000 description 22
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 17
229960000583 acetic acid Drugs 0.000 description 17
239000002253 acid Substances 0.000 description 17
239000000284 extract Substances 0.000 description 16
239000007787 solid Substances 0.000 description 16
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
229910052757 nitrogen Inorganic materials 0.000 description 15
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 14
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
239000003054 catalyst Substances 0.000 description 13
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 12
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 11
239000011734 sodium Substances 0.000 description 11
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
239000002904 solvent Substances 0.000 description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
238000003818 flash chromatography Methods 0.000 description 9
239000000741 silica gel Substances 0.000 description 9
229910002027 silica gel Inorganic materials 0.000 description 9
238000003756 stirring Methods 0.000 description 9
208000010110 spontaneous platelet aggregation Diseases 0.000 description 8
239000008280 blood Substances 0.000 description 7
210000004369 blood Anatomy 0.000 description 7
235000019359 magnesium stearate Nutrition 0.000 description 7
229920006395 saturated elastomer Polymers 0.000 description 7
229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
235000017557 sodium bicarbonate Nutrition 0.000 description 7
102000008946 Fibrinogen Human genes 0.000 description 6
108010049003 Fibrinogen Proteins 0.000 description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
229910021529 ammonia Inorganic materials 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
238000004587 chromatography analysis Methods 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
229940012952 fibrinogen Drugs 0.000 description 6
239000012065 filter cake Substances 0.000 description 6
239000000706 filtrate Substances 0.000 description 6
239000008101 lactose Substances 0.000 description 6
239000010410 layer Substances 0.000 description 6
229910052763 palladium Inorganic materials 0.000 description 6
239000001267 polyvinylpyrrolidone Substances 0.000 description 6
229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
238000002953 preparative HPLC Methods 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
229940124597 therapeutic agent Drugs 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
125000000217 alkyl group Chemical group 0.000 description 5
238000001816 cooling Methods 0.000 description 5
QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 5
238000009472 formulation Methods 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
229940086542 triethylamine Drugs 0.000 description 5
COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 5
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 4
239000002585 base Substances 0.000 description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
238000010828 elution Methods 0.000 description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
239000000543 intermediate Substances 0.000 description 4
239000012044 organic layer Substances 0.000 description 4
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
239000000843 powder Substances 0.000 description 4
238000010992 reflux Methods 0.000 description 4
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
239000012258 stirred mixture Substances 0.000 description 4
BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
238000007738 vacuum evaporation Methods 0.000 description 4
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
229920000881 Modified starch Polymers 0.000 description 3
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
238000005903 acid hydrolysis reaction Methods 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000006071 cream Substances 0.000 description 3
238000010511 deprotection reaction Methods 0.000 description 3
125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
201000010099 disease Diseases 0.000 description 3
239000003480 eluent Substances 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
239000003527 fibrinolytic agent Substances 0.000 description 3
238000011049 filling Methods 0.000 description 3
238000001914 filtration Methods 0.000 description 3
239000008187 granular material Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
150000004702 methyl esters Chemical class 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
150000007522 mineralic acids Chemical class 0.000 description 3
LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 3
YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 3
231100000241 scar Toxicity 0.000 description 3
229910000029 sodium carbonate Inorganic materials 0.000 description 3
239000012312 sodium hydride Substances 0.000 description 3
229910000104 sodium hydride Inorganic materials 0.000 description 3
239000011877 solvent mixture Substances 0.000 description 3
LKUCYFONIRHGSQ-UHFFFAOYSA-N tert-butyl 4-ethenylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C=C)CC1 LKUCYFONIRHGSQ-UHFFFAOYSA-N 0.000 description 3
229910052723 transition metal Inorganic materials 0.000 description 3
150000003624 transition metals Chemical class 0.000 description 3
FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 2
QDLYADRWMRXFEU-OWOJBTEDSA-N 2-[4-[3-carbamoyl-5-[(e)-2-piperidin-4-ylethenyl]indazol-1-yl]piperidin-1-yl]acetic acid Chemical compound C12=CC=C(\C=C\C3CCNCC3)C=C2C(C(=O)N)=NN1C1CCN(CC(O)=O)CC1 QDLYADRWMRXFEU-OWOJBTEDSA-N 0.000 description 2
QIULWQLXNFSZJG-UHFFFAOYSA-N 5-bromo-1h-indazole-3-carbonitrile Chemical compound BrC1=CC=C2NN=C(C#N)C2=C1 QIULWQLXNFSZJG-UHFFFAOYSA-N 0.000 description 2
BGLZAKHTTIEEMC-UHFFFAOYSA-N 5-bromo-3-methylsulfanyl-1h-indazole Chemical compound C1=C(Br)C=C2C(SC)=NNC2=C1 BGLZAKHTTIEEMC-UHFFFAOYSA-N 0.000 description 2
241000581479 Apodichthys Species 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
239000012359 Methanesulfonyl chloride Substances 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
239000003708 ampul Substances 0.000 description 2
210000001367 artery Anatomy 0.000 description 2
125000003710 aryl alkyl group Chemical group 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
239000008364 bulk solution Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000013078 crystal Substances 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 2
229910000071 diazene Inorganic materials 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
125000004185 ester group Chemical group 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
238000005984 hydrogenation reaction Methods 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
239000005457 ice water Substances 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
230000009401 metastasis Effects 0.000 description 2
UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
SPXDTAYVCQAZHH-CMDGGOBGSA-N methyl 5-[(e)-2-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]ethenyl]-1-[1-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]piperidin-4-yl]indazole-3-carboxylate Chemical compound C12=CC=C(\C=C\C3CCN(CC3)C(=O)OC(C)(C)C)C=C2C(C(=O)OC)=NN1C1CCN(CC(=O)OC(C)(C)C)CC1 SPXDTAYVCQAZHH-CMDGGOBGSA-N 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
239000008188 pellet Substances 0.000 description 2
230000035790 physiological processes and functions Effects 0.000 description 2
229910052697 platinum Inorganic materials 0.000 description 2
230000002980 postoperative effect Effects 0.000 description 2
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
239000008213 purified water Substances 0.000 description 2
JWHOQZUREKYPBY-UHFFFAOYSA-N rubonic acid Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(=O)C(C)(C)C5CC(=O)C34C)C2C1)C(=O)O JWHOQZUREKYPBY-UHFFFAOYSA-N 0.000 description 2
229940085605 saccharin sodium Drugs 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
235000010288 sodium nitrite Nutrition 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
WLTVUVZRHZKUJI-UHFFFAOYSA-N tert-butyl 2-[4-(5-bromo-3-methylsulfonylindazol-1-yl)piperidin-1-yl]acetate Chemical compound C1CN(CC(=O)OC(C)(C)C)CCC1N1C2=CC=C(Br)C=C2C(S(C)(=O)=O)=N1 WLTVUVZRHZKUJI-UHFFFAOYSA-N 0.000 description 2
WOEQSXAIPTXOPY-UHFFFAOYSA-N tert-butyl 4-methylsulfonyloxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(C)(=O)=O)CC1 WOEQSXAIPTXOPY-UHFFFAOYSA-N 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
229960000103 thrombolytic agent Drugs 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
230000002792 vascular Effects 0.000 description 2
239000002023 wood Substances 0.000 description 2
ZUSSRRHGFPZTLC-UHFFFAOYSA-N (2,4-dibromophenyl)-piperidin-4-ylmethanone Chemical class BrC1=CC(Br)=CC=C1C(=O)C1CCNCC1 ZUSSRRHGFPZTLC-UHFFFAOYSA-N 0.000 description 1
GYPCWHHQAVLMKO-XXKQIVDLSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-[(e)-n-[(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-ylidene)amino]-c-methylcarbonimidoyl]-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical group Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\N=C1CC(C)(C)N(O)C(C)(C)C1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 GYPCWHHQAVLMKO-XXKQIVDLSA-N 0.000 description 1
XVOUMQNXTGKGMA-OWOJBTEDSA-N (E)-glutaconic acid Chemical compound OC(=O)C\C=C\C(O)=O XVOUMQNXTGKGMA-OWOJBTEDSA-N 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
MVINXGMMFYXGDF-UHFFFAOYSA-N 1-acetylpiperidine-4-carbonyl chloride;hydrochloride Chemical compound Cl.CC(=O)N1CCC(C(Cl)=O)CC1 MVINXGMMFYXGDF-UHFFFAOYSA-N 0.000 description 1
MLRVZFYXUZQSRU-UHFFFAOYSA-N 1-chlorohexane Chemical compound CCCCCCCl MLRVZFYXUZQSRU-UHFFFAOYSA-N 0.000 description 1
XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
MKLLEEYEYOXUEJ-UHFFFAOYSA-N 2,2,2-tris(fluoranyl)ethanoic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.OC(=O)C(F)(F)F MKLLEEYEYOXUEJ-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
TXNRMUQNJBBBLI-UHFFFAOYSA-N 2-[4-[1-methylsulfonyl-6-(2-piperidin-4-ylethyl)indazol-3-yl]piperidin-1-yl]acetic acid Chemical compound C12=CC=C(CCC3CCNCC3)C=C2N(S(=O)(=O)C)N=C1C1CCN(CC(O)=O)CC1 TXNRMUQNJBBBLI-UHFFFAOYSA-N 0.000 description 1
UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical class C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
WDFQBORIUYODSI-UHFFFAOYSA-N 4-bromoaniline Chemical compound NC1=CC=C(Br)C=C1 WDFQBORIUYODSI-UHFFFAOYSA-N 0.000 description 1
YICWGVAOMZYNSI-UHFFFAOYSA-N 5-bromo-2-nitroindazole Chemical compound C1=C(Br)C=CC2=NN([N+](=O)[O-])C=C21 YICWGVAOMZYNSI-UHFFFAOYSA-N 0.000 description 1
ILGTYHMEQSSHFG-UHFFFAOYSA-N 5-bromo-2h-indazole-3-carbaldehyde Chemical compound C1=C(Br)C=CC2=NNC(C=O)=C21 ILGTYHMEQSSHFG-UHFFFAOYSA-N 0.000 description 1
OAKGUDRENHIOJQ-UHFFFAOYSA-N 5-bromo-3-methylsulfonyl-1-piperidin-4-ylindazole Chemical compound C12=CC=C(Br)C=C2C(S(=O)(=O)C)=NN1C1CCNCC1 OAKGUDRENHIOJQ-UHFFFAOYSA-N 0.000 description 1
QIHKDXICUWGQBR-UHFFFAOYSA-N 5-bromo-3-methylsulfonyl-2h-indazole Chemical compound C1=CC(Br)=CC2=C(S(=O)(=O)C)NN=C21 QIHKDXICUWGQBR-UHFFFAOYSA-N 0.000 description 1
AJJDLPCUYMSGQV-UHFFFAOYSA-N 6-bromo-3-piperidin-4-yl-2h-indazole;hydrochloride Chemical compound Cl.N=1NC2=CC(Br)=CC=C2C=1C1CCNCC1 AJJDLPCUYMSGQV-UHFFFAOYSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
229910015900 BF3 Inorganic materials 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
208000020084 Bone disease Diseases 0.000 description 1
206010065687 Bone loss Diseases 0.000 description 1
QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
241001480079 Corymbia calophylla Species 0.000 description 1
206010051055 Deep vein thrombosis Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
102100025027 E3 ubiquitin-protein ligase TRIM69 Human genes 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
101000830203 Homo sapiens E3 ubiquitin-protein ligase TRIM69 Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
208000037147 Hypercalcaemia Diseases 0.000 description 1
201000002980 Hyperparathyroidism Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
239000004367 Lipase Substances 0.000 description 1
102000004882 Lipase Human genes 0.000 description 1
108090001060 Lipase Proteins 0.000 description 1
235000006552 Liquidambar styraciflua Nutrition 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
208000029725 Metabolic bone disease Diseases 0.000 description 1
241001072332 Monia Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
206010049088 Osteopenia Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000018262 Peripheral vascular disease Diseases 0.000 description 1
208000035965 Postoperative Complications Diseases 0.000 description 1
208000010378 Pulmonary Embolism Diseases 0.000 description 1
239000007868 Raney catalyst Substances 0.000 description 1
229910000564 Raney nickel Inorganic materials 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
206010038908 Retinal vein thrombosis Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
208000032109 Transient ischaemic attack Diseases 0.000 description 1
241000863032 Trieres Species 0.000 description 1
229910052770 Uranium Inorganic materials 0.000 description 1
206010047249 Venous thrombosis Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
PAAZCQANMCYGAW-UHFFFAOYSA-N acetic acid;2,2,2-trifluoroacetic acid Chemical compound CC(O)=O.OC(=O)C(F)(F)F PAAZCQANMCYGAW-UHFFFAOYSA-N 0.000 description 1
GLRAHDCHUZLKKC-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid;hydrate Chemical compound O.CC#N.OC(=O)C(F)(F)F GLRAHDCHUZLKKC-UHFFFAOYSA-N 0.000 description 1
PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
238000009098 adjuvant therapy Methods 0.000 description 1
239000000556 agonist Substances 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
125000005599 alkyl carboxylate group Chemical group 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
235000011114 ammonium hydroxide Nutrition 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 1
239000012267 brine Substances 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
KDPAWGWELVVRCH-UHFFFAOYSA-M bromoacetate Chemical group [O-]C(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-M 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
USVVENVKYJZFMW-UHFFFAOYSA-N carboxyiminocarbamic acid Chemical compound OC(=O)N=NC(O)=O USVVENVKYJZFMW-UHFFFAOYSA-N 0.000 description 1
125000003262 carboxylic acid ester group Chemical group [H]C([H])([*:2])OC(=O)C([H])([H])[*:1] 0.000 description 1
150000001733 carboxylic acid esters Chemical class 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
229910052804 chromium Inorganic materials 0.000 description 1
239000011651 chromium Substances 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
239000004020 conductor Substances 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
WACQKHWOTAEEFS-UHFFFAOYSA-N cyclohexane;ethyl acetate Chemical compound CCOC(C)=O.C1CCCCC1 WACQKHWOTAEEFS-UHFFFAOYSA-N 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical class [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000013171 endarterectomy Methods 0.000 description 1
229960001123 epoprostenol Drugs 0.000 description 1
KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000003480 fibrinolytic effect Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000006260 foam Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000023597 hemostasis Effects 0.000 description 1
229940106780 human fibrinogen Drugs 0.000 description 1
238000007327 hydrogenolysis reaction Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000000148 hypercalcaemia Effects 0.000 description 1
208000030915 hypercalcemia disease Diseases 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
235000019421 lipase Nutrition 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
VMJMQRNRWGOEAE-UHFFFAOYSA-L lithium;potassium;carbonate Chemical compound [Li+].[K+].[O-]C([O-])=O VMJMQRNRWGOEAE-UHFFFAOYSA-L 0.000 description 1
239000002932 luster Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
GSYSFVSGPABNNL-UHFFFAOYSA-N methyl 2-dimethoxyphosphoryl-2-(phenylmethoxycarbonylamino)acetate Chemical group COC(=O)C(P(=O)(OC)OC)NC(=O)OCC1=CC=CC=C1 GSYSFVSGPABNNL-UHFFFAOYSA-N 0.000 description 1
DPXGLYOKETZFST-UHFFFAOYSA-N methyl 5-bromo-1-[1-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]piperidin-4-yl]indazole-3-carboxylate Chemical compound C12=CC=C(Br)C=C2C(C(=O)OC)=NN1C1CCN(CC(=O)OC(C)(C)C)CC1 DPXGLYOKETZFST-UHFFFAOYSA-N 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
150000005209 naphthoic acids Chemical class 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
125000006502 nitrobenzyl group Chemical group 0.000 description 1
230000000414 obstructive effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
238000005192 partition Methods 0.000 description 1
208000028169 periodontal disease Diseases 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
238000000746 purification Methods 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000003303 reheating Methods 0.000 description 1
208000004644 retinal vein occlusion Diseases 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
229910052703 rhodium Inorganic materials 0.000 description 1
239000010948 rhodium Substances 0.000 description 1
MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
JZWFDVDETGFGFC-UHFFFAOYSA-N salacetamide Chemical group CC(=O)NC(=O)C1=CC=CC=C1O JZWFDVDETGFGFC-UHFFFAOYSA-N 0.000 description 1
238000007789 sealing Methods 0.000 description 1
239000013049 sediment Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
JBFGMCGEFBDZTL-UHFFFAOYSA-N tert-butyl 2-[4-(5-bromo-3-carbamoylindazol-1-yl)piperidin-1-yl]acetate Chemical compound C1CN(CC(=O)OC(C)(C)C)CCC1N1C2=CC=C(Br)C=C2C(C(N)=O)=N1 JBFGMCGEFBDZTL-UHFFFAOYSA-N 0.000 description 1
UOUFRTFWWBCVPV-UHFFFAOYSA-N tert-butyl 4-(2,4-dioxo-1H-thieno[3,2-d]pyrimidin-3-yl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CC1)n1c(=O)[nH]c2ccsc2c1=O UOUFRTFWWBCVPV-UHFFFAOYSA-N 0.000 description 1
CCSOAUKKERHESX-CMDGGOBGSA-N tert-butyl 4-[(e)-2-[3-[1-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]piperidin-4-yl]-1-methylsulfonylindazol-6-yl]ethenyl]piperidine-1-carboxylate Chemical compound C1CN(CC(=O)OC(C)(C)C)CCC1C1=NN(S(C)(=O)=O)C2=CC(\C=C\C3CCN(CC3)C(=O)OC(C)(C)C)=CC=C12 CCSOAUKKERHESX-CMDGGOBGSA-N 0.000 description 1
FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
230000002537 thrombolytic effect Effects 0.000 description 1
230000001732 thrombotic effect Effects 0.000 description 1
RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
201000010875 transient cerebral ischemia Diseases 0.000 description 1
KQTIIICEAUMSDG-UHFFFAOYSA-N tricarballylic acid Chemical class OC(=O)CC(C(O)=O)CC(O)=O KQTIIICEAUMSDG-UHFFFAOYSA-N 0.000 description 1
125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
238000001665 trituration Methods 0.000 description 1
238000004879 turbidimetry Methods 0.000 description 1
238000005292 vacuum distillation Methods 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Plural Heterocyclic Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

JP10502284A 1996-06-21 1997-06-19 ピペリジン酢酸誘導体および血栓障害の治療におけるそれらの使用 Pending JP2000512648A (ja)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
GB9613018.2		1996-06-21
GB9613095.0		1996-06-21
GBGB9613017.4A GB9613017D0 (en)	1996-06-21	1996-06-21	Therapeutic compounds
GB9613017.4		1996-06-21
GBGB9613095.0A GB9613095D0 (en)	1996-06-21	1996-06-21	Therapeutic piperidines
GBGB9613018.2A GB9613018D0 (en)	1996-06-21	1996-06-21	Therapeutic indazoles
PCT/EP1997/003196 WO1997049699A1 (en)	1996-06-21	1997-06-19	Piperidine acetic acid derivatives and their use in the treatment of thrombotic disorders

Publications (1)

Publication Number	Publication Date
JP2000512648A true JP2000512648A (ja)	2000-09-26

Family

ID=27268341

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP10502284A Pending JP2000512648A (ja)	1996-06-21	1997-06-19	ピペリジン酢酸誘導体および血栓障害の治療におけるそれらの使用

Country Status (17)

Country	Link
EP (1)	EP0912555A1 (id)
JP (1)	JP2000512648A (id)
KR (1)	KR20000022041A (id)
AP (1)	AP9801417A0 (id)
AR (1)	AR008245A1 (id)
AU (1)	AU3261197A (id)
BR (1)	BR9709930A (id)
CA (1)	CA2258753A1 (id)
CZ (1)	CZ424698A3 (id)
EA (1)	EA199801015A1 (id)
ID (1)	ID17052A (id)
IL (1)	IL127464A0 (id)
IS (1)	IS4924A (id)
NO (1)	NO985974L (id)
PL (1)	PL330797A1 (id)
TR (1)	TR199802665T2 (id)
WO (1)	WO1997049699A1 (id)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2005536520A (ja) *	2002-07-18	2005-12-02	ワイス	５−ヒドロキシトリプタミン−６リガンドとしての１−（ヘテロサイクリルアルキル）−３−スルホニルインドールまたはインダゾール誘導体
JP2006518385A (ja) *	2003-02-14	2006-08-10	ワイス	５−ヒドロキシトリプタミン−６リガンドとしてのヘテロサイクリル−３−スルホニルインダゾール

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7642278B2 (en)	2001-07-03	2010-01-05	Novartis Vaccines And Diagnostics, Inc.	Indazole benzimidazole compounds
JP2004536113A (ja)	2001-07-03	2004-12-02	カイロンコーポレイション	チロシンキナーゼおよびセリン／スレオニンキナーゼのインヒビターとしてのインダゾールベンズイミダゾール化合物
BRPI0709718A2 (pt)	2006-04-05	2011-03-29	Wyeth Corp	composto; método para tratamento de um transtorno do sistema nervoso central relacionado a ou afetado pelo receptor 5-ht6 em um paciente necessitado; composição farmacêutica; e proceso para a preparação do composto
JP5208963B2 (ja)	2007-01-10	2013-06-12	エフ．ホフマン−ラロシュアーゲー	キマーゼ阻害剤としてのスルホンアミド誘導体
CN113655155A (zh) *	2021-07-28	2021-11-16	任贤金	一种测定sph3127有关物质的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4124942A1 (de) *	1991-07-27	1993-01-28	Thomae Gmbh Dr K	5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
JPH07501063A (ja) *	1991-11-14	1995-02-02	グラクソ、グループ、リミテッド	フィブリノーゲン依存性血小板凝集阻害剤としてのピペリジン酢酸誘導体
GB9208740D0 (en) *	1992-04-23	1992-06-10	Glaxo Group Ltd	Chemical compounds

1997
- 1997-06-18 AR ARP970102676A patent/AR008245A1/es unknown
- 1997-06-19 KR KR1019980710439A patent/KR20000022041A/ko not_active Withdrawn
- 1997-06-19 PL PL97330797A patent/PL330797A1/xx unknown
- 1997-06-19 BR BR9709930A patent/BR9709930A/pt not_active Application Discontinuation
- 1997-06-19 IL IL12746497A patent/IL127464A0/xx unknown
- 1997-06-19 WO PCT/EP1997/003196 patent/WO1997049699A1/en not_active Ceased
- 1997-06-19 JP JP10502284A patent/JP2000512648A/ja active Pending
- 1997-06-19 CZ CZ984246A patent/CZ424698A3/cs unknown
- 1997-06-19 TR TR1998/02665T patent/TR199802665T2/xx unknown
- 1997-06-19 AU AU32611/97A patent/AU3261197A/en not_active Abandoned
- 1997-06-19 ID IDP972092A patent/ID17052A/id unknown
- 1997-06-19 AP APAP/P/1998/001417A patent/AP9801417A0/en unknown
- 1997-06-19 EP EP97928243A patent/EP0912555A1/en not_active Withdrawn
- 1997-06-19 CA CA002258753A patent/CA2258753A1/en not_active Abandoned
- 1997-06-19 EA EA199801015A patent/EA199801015A1/ru unknown
1998
- 1998-12-15 IS IS4924A patent/IS4924A/is unknown
- 1998-12-18 NO NO985974A patent/NO985974L/no not_active Application Discontinuation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2005536520A (ja) *	2002-07-18	2005-12-02	ワイス	５−ヒドロキシトリプタミン−６リガンドとしての１−（ヘテロサイクリルアルキル）−３−スルホニルインドールまたはインダゾール誘導体
JP2006518385A (ja) *	2003-02-14	2006-08-10	ワイス	５−ヒドロキシトリプタミン−６リガンドとしてのヘテロサイクリル−３−スルホニルインダゾール

Also Published As

Publication number	Publication date
EP0912555A1 (en)	1999-05-06
NO985974D0 (no)	1998-12-18
AP9801417A0 (en)	1998-12-31
CZ424698A3 (cs)	1999-05-12
EA199801015A1 (ru)	1999-08-26
BR9709930A (pt)	1999-08-10
KR20000022041A (ko)	2000-04-25
IS4924A (is)	1998-12-15
NO985974L (no)	1999-02-17
IL127464A0 (en)	1999-10-28
AU3261197A (en)	1998-01-14
ID17052A (id)	1997-12-04
CA2258753A1 (en)	1997-12-31
PL330797A1 (en)	1999-06-07
TR199802665T2 (xx)	1999-03-22
AR008245A1 (es)	1999-12-29
WO1997049699A1 (en)	1997-12-31

Publication	Publication Date	Title
AU611469B2 (en)	1991-06-13	Indole derivatives
CN112789087B (zh)	2024-08-13	Pad酶的苯并咪唑抑制剂
JP2021534106A (ja)	2021-12-09	Ｐａｄ４阻害剤としての置換チエノピロール
JPH11502810A (ja)	1999-03-09	ニューロキニンアンタゴニストとしての３−ベンジルアミノ−２−フェニルピペリジン
JPH11503167A (ja)	1999-03-23	タキキニン受容体拮抗物質としての２−アシルアミノプロパンアミド類
JP2001514227A (ja)	2001-09-11	ピラジノン系トロンビン阻害薬
JP2001505193A (ja)	2001-04-17	ベンズアミド誘導体
JP2000508334A (ja)	2000-07-04	ピラジノン系トロンビン阻害薬
JP2002529531A (ja)	2002-09-10	４−アロイルピペリジンｃｃｒ−３受容体拮抗剤ｉｉｉ
JP2021534097A (ja)	2021-12-09	Ｐａｄ４阻害剤としての置換ベンズイミダゾール
AU2004234069A1 (en)	2004-11-11	Quinuclidine derivatives binding to mucarinic M3 receptors
JP2000508307A (ja)	2000-07-04	凝集阻止作用を有するカルボン酸誘導体
JPH10511375A (ja)	1998-11-04	フィブリノゲン拮抗剤として有用なピペリジン酢酸誘導体
JP2002513790A (ja)	2002-05-14	Ｘａ因子を阻害する複素環誘導体
JPH11501041A (ja)	1999-01-26	Ｅａａアンタゴニストとしてのインドール誘導体
JPH08502474A (ja)	1996-03-19	トコリティックオキシトシンレセプターアンタゴニスト
JPH06510782A (ja)	1994-12-01	５−ｈｔ作動薬および拮抗薬としてのピロロベンズオキサジン誘導体
JP2008520644A (ja)	2008-06-19	オクタヒドロピロロ［３，４−ｃ］ピロール誘導体
KR20000022041A (ko)	2000-04-25	피페리딘 아세트산 유도체 및 혈전성 질환 치료에서의 그의용도
WO1997049698A1 (en)	1997-12-31	Piperidine acetic acid derivatives and their use in the treatment of thrombotic disorders
US5602149A (en)	1997-02-11	1-OXO-2-(phenylsulphonylamino)pentypiperidine derivatives, their preparation and their therapeutic application
EP0964684B1 (en)	2003-07-30	Crystalline pharmaceutical product
JP2011153136A (ja)	2011-08-11	ビフェニル−２−イル−カルバミン酸１−｛９−［（３−フルオロ−４−ヒドロキシ−ベンゾイル）−メチル−アミノ］−ノニル｝−ピペリジン−４−イルエステル塩酸塩
JP2941702B2 (ja)	1999-08-30	５‐ｈｔ３レセプターにおいて５‐ｈｔの作用に拮抗するラクタム誘導体を含む医薬組成物
JP2004520399A (ja)	2004-07-08	トロンビン阻害剤

JP2000512648A - ピペリジン酢酸誘導体および血栓障害の治療におけるそれらの使用 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (7)

Publications (1)

Family

ID=27268341

Family Applications (1)

Country Status (17)

Cited By (2)

Families Citing this family (5)

Family Cites Families (3)

Cited By (2)

Also Published As

Similar Documents